E
BioForce Nanosciences Holdings, Inc.
BFNH
$0.60
$0.2466.67%
E
Sell
3/14/2023Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/9/2023Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 02/09/2023.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index. Operating cash flow declined 70.83% from -$9.6 to -$16.4, EBIT declined 5.87% from -$115.8 to -$122.6, and earnings per share declined from -$0.004 to -$0.0042.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index. Operating cash flow declined 70.83% from -$9.6 to -$16.4, EBIT declined 5.87% from -$115.8 to -$122.6, and earnings per share declined from -$0.004 to -$0.0042.
D
Sell
5/16/2022Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 05/16/2022.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index. The quick ratio declined from 0.01 to 0.01.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index. The quick ratio declined from 0.01 to 0.01.
D
Sell
5/4/2022Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 05/04/2022.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 05/01/2022.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, growth index and solvency index. The quick ratio declined from 0.04 to 0.01, debt to equity increased from -0.17 to -0.13, and EBIT declined 5.97% from -$113.9 to -$120.7.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, growth index and solvency index. The quick ratio declined from 0.04 to 0.01, debt to equity increased from -0.17 to -0.13, and EBIT declined 5.97% from -$113.9 to -$120.7.
D
Sell
12/2/2021Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 12/2/2021 due to an increase in the total return index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 12/2/2021 due to an increase in the total return index and volatility index.
D
Sell
11/23/2021Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and volatility index.
E
Sell
11/8/2021Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 0.04 to 0.04, and debt to equity increased from -0.18 to -0.17.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 0.04 to 0.04, and debt to equity increased from -0.18 to -0.17.
D
Sell
9/7/2021Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 9/7/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.06 to 0.04.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 9/7/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.06 to 0.04.
D
Sell
5/17/2021Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 5/17/2021 due to an increase in the total return index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 5/17/2021 due to an increase in the total return index and volatility index.
D
Sell
4/28/2021Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 4/28/2021 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0063 to -$0.005.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 4/28/2021 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0063 to -$0.005.
E
Sell
2/17/2021Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 2/17/2021 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.14 to 0.1, and debt to equity increased from -0.23 to -0.19.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 2/17/2021 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.14 to 0.1, and debt to equity increased from -0.23 to -0.19.
D
Sell
2/12/2021Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 2/12/2021 due to an increase in the volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from E+ on 2/12/2021 due to an increase in the volatility index.
E
Sell
1/12/2021Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 1/12/2021 due to a large decline in the total return index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to E+ from D- on 1/12/2021 due to a large decline in the total return index and volatility index.
D
Sell
11/30/2020Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 11/30/2020 due to a noticeable decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.25 to 0.14, and debt to equity increased from -0.39 to -0.23.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 11/30/2020 due to a noticeable decline in the solvency index, total return index and volatility index. The quick ratio declined from 0.25 to 0.14, and debt to equity increased from -0.39 to -0.23.
D
Sell
7/23/2020Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 7/23/2020 due to a noticeable increase in the valuation index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 7/23/2020 due to a noticeable increase in the valuation index.
D
Sell
5/20/2020Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 5/20/2020 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0013 to -$10.3491, EBIT declined 782,283.17% from -$20.2 to -$158.04M, and operating cash flow declined 284.47% from -$10.3 to -$39.6.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 5/20/2020 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0013 to -$10.3491, EBIT declined 782,283.17% from -$20.2 to -$158.04M, and operating cash flow declined 284.47% from -$10.3 to -$39.6.
D
Sell
5/1/2020Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 05/01/2020.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 05/01/2020.
D
Sell
11/6/2019Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 11/6/2019 due to a decline in the growth index, efficiency index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 11/6/2019 due to a decline in the growth index, efficiency index and volatility index.
D
Sell
7/23/2019Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 7/23/2019 due to a noticeable increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.0002 to -$0.0001, EBIT increased 44.19% from -$12.9 to -$7.2, and net income increased 44.19% from -$12.9 to -$7.2.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 7/23/2019 due to a noticeable increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.0002 to -$0.0001, EBIT increased 44.19% from -$12.9 to -$7.2, and net income increased 44.19% from -$12.9 to -$7.2.
D
Sell
10/25/2018Downgrade
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 10/25/2018 due to a decline in the efficiency index.
BioForce Nanosciences Holdings, Inc. (BFNH) was downgraded to D- from D on 10/25/2018 due to a decline in the efficiency index.
D
Sell
5/22/2018Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 5/22/2018 due to a large increase in the solvency index, efficiency index and growth index. Total capital increased 71.95% from $8.2 to $14.1, the quick ratio increased from 1.48 to 2.2, and net income increased 2.83% from -$24.7 to -$24.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D from D- on 5/22/2018 due to a large increase in the solvency index, efficiency index and growth index. Total capital increased 71.95% from $8.2 to $14.1, the quick ratio increased from 1.48 to 2.2, and net income increased 2.83% from -$24.7 to -$24.
D
Sell
4/13/2018Upgraded
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from on 4/13/2018 due to a significant increase in the total return index, solvency index and volatility index.
BioForce Nanosciences Holdings, Inc. (BFNH) was upgraded to D- from on 4/13/2018 due to a significant increase in the total return index, solvency index and volatility index.
OTC PK
03/05/2025 8:30AM Eastern
Quotes delayed
